gdc
FDA Approvals, News & UpdatesLiver CancerNewsworthy

Stivarga and Opdivo Newest Treatments for Liver Cancer

In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
December 2017 Vol 3 No 6

On April 27, 2017, the FDA approved Stivarga (regorafenib, from Bayer HealthCare) for the treatment of patients with the most common type of liver cancer, called hepatocellular carcinoma (HCC), after they received sorafenib.

Stivarga, a kinase inhibitor that blocks the activity of several enzymes that promote cancer growth, is the first drug in almost a decade to be approved by the FDA for liver cancer. Stivarga was previously approved for the treatment of patients with colorectal cancer or gastrointestinal stromal tumors that stopped responding to other treatments.

On September 26, 2017, the FDA approved Opdivo (nivolumab, from Bristol-Myers Squibb), for patients with HCC, after being treated with sorafenib. Opdivo is the first immunotherapy approved by the FDA for patients with HCC and the second new treatment approved in the past decade for liver cancer.

The FDA approval of Opdivo for liver cancer was based on a study showing that 22 patients responded to treatment with Opdivo; of these patients, the cancer was in complete remission in 3 patients after treatment with Opdivo, and 19 patients saw their tumors shrink significantly. Opdivo was previously approved for many other types of cancer.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Last modified: January 23, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country